Clinical Trial

Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)

Name: Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study) — clinical trial record (NCT07564947)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GL-MAFLD-NFR2

Enrolling by Invitation

View on ClinicalTrials.gov →

Summary

This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.

Trial Details

NCT Number	NCT07564947
Lead Sponsor	University of Agriculture, Peshawar
Conditions	MAFLD, Fatty Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Fatty Liver Disease, Oxidative Stress, Inflammation
Enrollment	40 participants
Start Date	2026-04-28
Primary Completion	2027-04-20 (estimated)
Study Completion	2027-04-20 (estimated)
Updated on ClinicalTrials.gov	2026-05-04